1. Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years
- Author
-
Michelle A. Neller, George R. Ambalathingal, Nada Hamad, Joe Sasadeusz, Rebecca Pearson, Chien-Li Holmes-Liew, Deepak Singhal, Matthew Tunbridge, Wei Yang Ng, Kirsty Sharplin, Andrew Moore, David Deambrosis, Trisha Soosay-Raj, Peter McNaughton, Morag Whyte, Chris Fraser, Andrew Grigg, David Kliman, Ashish Bajel, Katherine Cummins, Mark Dowling, Zhi Han Yeoh, Simon J. Harrison, Amit Khot, Sarah Tan, Izanne Roos, Ray Mun Koo, Sara Dohrmann, David Ritchie, Brynn Wainstein, Karen McCleary, Adam Nelson, Bradley Gardiner, Shafqat Inam, Xavier Badoux, Kris Ma, Claudia Toro, Diane Hanna, David Hughes, Rachel Conyers, Theresa Cole, Shiqi Stacie Wang, Lynette Chee, Jacqueline Fleming, Ashley Irish, Duncan Purtill, Julian Cooney, Peter Shaw, Siok-Keen Tey, Stewart Hunt, Elango Subramonia Pillai, George John, Michelle Ng, Shanti Ramachandran, Peter Hopkins, Daniel Chambers, Scott Campbell, Ross Francis, Nicole Isbel, Paula Marlton, Hilary Reddiex, Katherine K. Matthews, Meggie Voogt, Archana Panikkar, Leone Beagley, Sweera Rehan, Shannon Best, Jyothy Raju, Laetitia Le Texier, Pauline Crooks, Matthew Solomon, Lea Lekieffre, Sriganesh Srihari, Corey Smith, and Rajiv Khanna
- Subjects
Science - Abstract
Abstract Adoptive T-cell immunotherapy holds great promise for the treatment of viral complications in immunocompromised patients resistant to standard anti-viral strategies. We present a retrospective analysis of 78 patients from 19 hospitals across Australia and New Zealand, treated over the last 15 years with “off-the-shelf” allogeneic T cells directed to a combination of Epstein–Barr virus (EBV), cytomegalovirus (CMV), BK polyomavirus (BKV), John Cunningham virus (JCV) and/or adenovirus (AdV) under the Australian Therapeutic Goods Administration’s Special Access Scheme. Most patients had severe post-transplant viral complications, including drug-resistant end-organ CMV disease, BKV-associated haemorrhagic cystitis and EBV-driven post-transplant lymphoproliferative disorder. Adoptive immunotherapy is well tolerated with few adverse effects. Importantly, 46/71 (65%) patients show definitive clinical improvement including reduction in viral load, clinical symptoms and complete resolution of end-organ disease. In addition, seven high-risk patients remain disease free. Based on this long-term encouraging clinical experience, we propose that a dedicated nationally funded centre for anti-viral cellular therapies should be considered to provide T cell therapies for critically ill patients for compassionate use.
- Published
- 2024
- Full Text
- View/download PDF